Fig. 6: CDC37L1 and PPIA predict poor prognosis of HCC patients subjected to sorafenib therapy. | Cell Death Discovery

Fig. 6: CDC37L1 and PPIA predict poor prognosis of HCC patients subjected to sorafenib therapy.

From: miR-15a and miR-20b sensitize hepatocellular carcinoma cells to sorafenib through repressing CDC37L1 and consequent PPIA downregulation

Fig. 6

A Representative images of IHC staining of CDC37L1 and PPIA in normal and HCC tumor tissues. B Quantification of CDC37L1 and PPIA protein levels in 80 pairs of normal and HCC tissues (n = 80, paired t test, two-tailed). C Representative images of IHC staining of CDC37L1 and PPIA in consecutive HCC tissues. D The expression correlation of CDC37L1 and PPIA in (C) was analyzed. E, F Overall survival and disease-free survival of CDC37L1 or PPIA-high and −low group patients (n = 80, log-rank test). Scale bars: 25 μm.

Back to article page